• Record: found
  • Abstract: found
  • Article: not found

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.

      Related collections

      Author and article information

      [1 ] From the Mayo Clinic, Rochester, MN (S.M.A.); Memorial Sloan Kettering Cancer Center (A.M.L., D.C.) and Weill Cornell Medical College (A.M.L.) - both in New York; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore (I.B.); University of Utah Huntsman Cancer Institute, Salt Lake City (A.H.); Oregon Health and Science University and the Knight Cancer Institute, Portland (E.C.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack (M.G.), and Bristol-Myers Squibb, Lawrenceville (L.Z., J.F.G., S.Y.K.) - both in New Jersey; Abramson Cancer Center, University of Pennsylvania (S.J.S.), and Fox Chase Cancer Center (M.M.M.) - both in Philadelphia; Dana-Farber Cancer Institute (G.J.F., B.C., M.A.S., P.A.) Brigham and Women's Hospital (S.J.R., A.H.L.), and Harvard Medical School (G.J.F., B.C., M.A.S., P.A., S.J.R., A.H.L.) - all in Boston; and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (J.M.T.).
      N. Engl. J. Med.
      The New England journal of medicine
      New England Journal of Medicine (NEJM/MMS)
      Jan 22 2015
      : 372
      : 4


      Comment on this article